ADXN:NSD-Addex Therapeutics Ltd (USD)

COMMON STOCK | | NSD

Last Closing Price

USD 10.25

Change

0.00 (0.00)%

Market Cap

USD 0.07B

Volume

9.95K

Average Target Price

USD 28.00 (+173.17%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds for the treatment of human health. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-20 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BOKFL BOK Financial Corporation

N/A

USD5.32B 3.46 N/A
HCACW Hennessy Capital Acquisition C..

N/A

USD3.34B 11.29 N/A
TCBIL Texas Capital Bancshares, Inc

N/A

USD2.88B 8.82 N/A
DFH Dream Finders Homes, Inc

N/A

USD2.16B N/A 22.78
OPINI Office Properties Income Trust

N/A

USD1.26B 36.29 N/A
ARKO Arko Corp

N/A

USD1.18B N/A 16.57
EOSE Eos Energy Enterprises, Inc

N/A

USD1.00B N/A N/A
CLNN Clene Inc

N/A

USD0.72B N/A N/A
FTACW FinTech Acquisition Corp. III

N/A

USD0.63B 5.88 N/A
BTAQU Burgundy Technology Acquisitio..

N/A

USD0.44B N/A N/A

ETFs Containing ADXN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification ()
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.51% N/A N/A 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.51% N/A N/A 11% F
Trailing 12 Months  
Capital Gain 5.67% N/A N/A 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.67% N/A N/A 23% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 7.45% N/A N/A 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.45% N/A N/A 45% F
Risk Return Profile  
Volatility (Standard Deviation) 17.26% N/A N/A 82% B-
Risk Adjusted Return 43.14% N/A N/A 62% D-
Market Capitalization 0.07B N/A N/A 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
()
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 N/A N/A 100% A+
Price/Book Ratio 3.43 N/A N/A 43% F
Price / Cash Flow Ratio -6.11 N/A N/A 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.69% N/A N/A 21% F
Return on Invested Capital -61.01% N/A N/A 13% F
Return on Assets -24.93% N/A N/A 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.20 N/A N/A 93% A
Short Percent 0.03% N/A N/A 97% A+
Beta 1.35 N/A N/A 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.